Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy-

Request For Quotation
Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy- Suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +17819995354
Email: marketing@targetmol.com
Products Intro: Product Name:HDAC1/MAO-B-IN-1
CAS:2759855-37-1
Package:50mg;1980USD|25mg;1520USD|100mg;2500USD
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Products Intro: Product Name:HDAC1/MAO-B-IN-1
CAS:2759855-37-1
Package:1removed

Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy- manufacturers

  • HDAC1/MAO-B-IN-1
  • HDAC1/MAO-B-IN-1 pictures
  • $1980.00 / 50mg
  • 2026-05-11
  • CAS:2759855-37-1
  • Min. Order:
  • Purity:
  • Supply Ability: 10g
Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy- Basic information
Product Name:Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy-
Synonyms:Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy-;HDAC1/MAO-B-IN-1
CAS:2759855-37-1
MF:C18H17ClN2O2
MW:328.8
EINECS:
Product Categories:
Mol File:2759855-37-1.mol
Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy- Structure
Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy- Chemical Properties
density 1.280±0.06 g/cm3(Predicted)
pka8.88±0.10(Predicted)
Safety Information
MSDS Information
Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy- Usage And Synthesis
UsesHDAC1/MAO-B-IN-1 is a potent, selective and cross the blood-brain barrier HDAC1/MAO-B inhibitor with IC50 values of 21.4 nM and 99.0 nM for HDAC1 and MAO-B, respectively. HDAC1/MAO-B-IN-1 has the potential for the research of Alzheimer’s disease[1].
in vivo

HDAC1/MAO-B-IN-1 (20 mg/kg; i.g.) exhibits favorable BBB (blood–brain barrier) permeability[1].
HDAC1/MAO-B-IN-1 (15 mg/kg; i.p.) improves the learning and memory abilities of the ICR mice[1].

Animal Model:6-8 weeks, ICR male mice[1]
Dosage:20 mg/kg
Administration:I.g.
Result:Exhibited favorable BBB (blood–brain barrier) permeability.
Animal Model:20-25 g, ICR female mice[1]
Dosage:15 mg/kg
Administration:I.p.; 15 consecutive days
Result:Improved the learning and memory abilities of the ICR mice.
IC 50HDAC1: 21.4 nM (IC50); MAO-B: 99.0 nM (IC50)
References[1] Yao C, et al. HDAC1/MAO-B dual inhibitors against Alzheimer's disease: Design, synthesis and biological evaluation of N-propargylamine-hydroxamic acid/o-aminobenzamide hybrids. Bioorg Chem. 2022; 122:105724. DOI:10.1016/j.bioorg.2022.105724
Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy- Preparation Products And Raw materials
Tag:Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy-(2759855-37-1) Related Product Information